Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Tatenda Gochera
Observed name:
Gochera, T.
Observed institutions:
St James's University Hospital,
Weston Park Cancer Centre,
Sheffield Teaching Hospitals NHS Foundation Trust,
Wellcome Trust
ORCID:
0009-0000-6797-0376
Observed ORCID:
0009-0000-6797-0376
OpenAlex ID:
A5092265040
Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
2023
·
Christopher J.M. Williams
, Faye Elliott
, et al.
·
Clinical Cancer Research
·
23
PDF
Supplementary Methods S1 from Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
2025
·
Christopher J.M. Williams
, Faye Elliott
, et al.
Supplementary Figure S3 from Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
2025
·
Christopher J.M. Williams
, Faye Elliott
, et al.
PDF
Supplementary Table S3 from Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
2025
·
Christopher J.M. Williams
, Faye Elliott
, et al.
PDF
Supplementary Figure S2 from Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
2025
·
Christopher J.M. Williams
, Faye Elliott
, et al.
Supplementary Table S2 from Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
2025
·
Christopher J.M. Williams
, Faye Elliott
, et al.
PDF
Supplementary Table S1 from Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
2025
·
Christopher J.M. Williams
, Faye Elliott
, et al.
PDF
Supplementary Figure S1 from Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
2025
·
Christopher J.M. Williams
, Faye Elliott
, et al.
PDF
Supplementary Figure S3 from Associations between AI-assisted tumor amphiregulin and epiregulin IHC and outcomes from anti-EGFR therapy in the routine management of metastatic colorectal cancer
2024
·
Christopher J.M. Williams
, Faye Elliott
, et al.
Supplementary Table S3 from Associations between AI-assisted tumor amphiregulin and epiregulin IHC and outcomes from anti-EGFR therapy in the routine management of metastatic colorectal cancer
2024
·
Christopher J.M. Williams
, Faye Elliott
, et al.
Supplementary Figure S1 from Associations between AI-assisted tumor amphiregulin and epiregulin IHC and outcomes from anti-EGFR therapy in the routine management of metastatic colorectal cancer
2024
·
Christopher J.M. Williams
, Faye Elliott
, et al.
Supplementary Table S2 from Associations between AI-assisted tumor amphiregulin and epiregulin IHC and outcomes from anti-EGFR therapy in the routine management of metastatic colorectal cancer
2024
·
Christopher J.M. Williams
, Faye Elliott
, et al.
Supplementary Table S1 from Associations between AI-assisted tumor amphiregulin and epiregulin IHC and outcomes from anti-EGFR therapy in the routine management of metastatic colorectal cancer
2024
·
Christopher J.M. Williams
, Faye Elliott
, et al.
Supplementary Methods S1 from Associations between AI-assisted tumor amphiregulin and epiregulin IHC and outcomes from anti-EGFR therapy in the routine management of metastatic colorectal cancer
2024
·
Christopher J.M. Williams
, Faye Elliott
, et al.
Supplementary Figure S3 from Associations between AI-assisted tumor amphiregulin and epiregulin IHC and outcomes from anti-EGFR therapy in the routine management of metastatic colorectal cancer
2024
·
Christopher J.M. Williams
, Faye Elliott
, et al.
Supplementary Table S3 from Associations between AI-assisted tumor amphiregulin and epiregulin IHC and outcomes from anti-EGFR therapy in the routine management of metastatic colorectal cancer
2024
·
Christopher J.M. Williams
, Faye Elliott
, et al.
Supplementary Figure S1 from Associations between AI-assisted tumor amphiregulin and epiregulin IHC and outcomes from anti-EGFR therapy in the routine management of metastatic colorectal cancer
2024
·
Christopher J.M. Williams
, Faye Elliott
, et al.
Supplementary Figure S2 from Associations between AI-assisted tumor amphiregulin and epiregulin IHC and outcomes from anti-EGFR therapy in the routine management of metastatic colorectal cancer
2024
·
Christopher J.M. Williams
, Faye Elliott
, et al.
Supplementary Table S1 from Associations between AI-assisted tumor amphiregulin and epiregulin IHC and outcomes from anti-EGFR therapy in the routine management of metastatic colorectal cancer
2024
·
Christopher J.M. Williams
, Faye Elliott
, et al.
Supplementary Table S2 from Associations between AI-assisted tumor amphiregulin and epiregulin IHC and outcomes from anti-EGFR therapy in the routine management of metastatic colorectal cancer
2024
·
Christopher J.M. Williams
, Faye Elliott
, et al.
Supplementary Figure S2 from Associations between AI-assisted tumor amphiregulin and epiregulin IHC and outcomes from anti-EGFR therapy in the routine management of metastatic colorectal cancer
2024
·
Christopher J.M. Williams
, Faye Elliott
, et al.
Supplementary Figure S3 from Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
2023
·
Christopher J.M. Williams
, Faye Elliott
, et al.
PDF
Supplementary Methods S1 from Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
2023
·
Christopher J.M. Williams
, Faye Elliott
, et al.
Supplementary Table S2 from Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
2023
·
Christopher J.M. Williams
, Faye Elliott
, et al.
Supplementary Figure S1 from Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
2023
·
Christopher J.M. Williams
, Faye Elliott
, et al.
PDF
Show more works
View as search
Works count:
45
Citation count:
23
H-index:
1
I10-index:
1
Year
Topic
Type
